Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis
Abstract Background Controversial results still existed on the clinical utility of bone marrow-derived cells (BMCs) for cardiomyopathy (CMP). This study aims to reveal the true power of this promising approach by synthesizing all the available data on this subject matter. Methods Twenty studies incl...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13287-019-1238-5 |
| _version_ | 1811285315025895424 |
|---|---|
| author | Chao Wang Jingzhao Li Boya Zhang Yongjian Li |
| author_facet | Chao Wang Jingzhao Li Boya Zhang Yongjian Li |
| author_sort | Chao Wang |
| collection | DOAJ |
| description | Abstract Background Controversial results still existed on the clinical utility of bone marrow-derived cells (BMCs) for cardiomyopathy (CMP). This study aims to reveal the true power of this promising approach by synthesizing all the available data on this subject matter. Methods Twenty studies including 1418 patients were identified from systematic search. Weighted mean differences for changes in left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), 6-min walk distance, and NYHA functional class were estimated with a random-effects model. Major adverse cardiovascular event (MACE), rehospitalization, all-cause mortality, and patients’ quality of life were also calculated. Results Compared with the control group, BMC therapy resulted in greater LVEF (3.72%, 95% CI 2.31 to 5.13, P < 0.0001), 6-min walk distance (53.16, 95% CI 25.17 to 81.10, P = 0.0002), NYHA functional class (− 0.48, 95% CI − 0.65 to − 0.31, P < 0.0001), and smaller LVESV (− 16.79, 95% CI − 27.21 to − 6.38, P = 0.002). BMC treatment significantly reduced the mortality rate and improved patients’ quality of life. No significant difference was found between the BMCs and control group in LVEDV, MACE, and rehospitalization rate. However, the outcomes showed a clear trend in favor of the BMC group. Subgroup analysis showed that LVEF improved greater in a subgroup of intracoronary infusion, BMSC, or higher cell dose. Conclusion The results of the current meta-analysis suggest that BMC treatment for CMP is safe and feasible. This therapy was associated with persistent improvements in LV function, LV remodeling, functional class, patients’ survival, and quality of life. Intracoronary infusion of high-dose (> 108) BMSC might be a better therapeutic option for CMP patients. Further evidences are needed to verify our results. |
| first_indexed | 2024-04-13T02:42:09Z |
| format | Article |
| id | doaj.art-83aee704411b4240a9ec684b38e84a5e |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-04-13T02:42:09Z |
| publishDate | 2019-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-83aee704411b4240a9ec684b38e84a5e2022-12-22T03:06:10ZengBMCStem Cell Research & Therapy1757-65122019-05-0110111210.1186/s13287-019-1238-5Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysisChao Wang0Jingzhao Li1Boya Zhang2Yongjian Li3Department of Cardiology, Tianjin Nankai HospitalDepartment of Cardiology, Tianjin Nankai HospitalDepartment of Cardiology, Tianjin Nankai HospitalDepartment of Cardiology, Tianjin Nankai HospitalAbstract Background Controversial results still existed on the clinical utility of bone marrow-derived cells (BMCs) for cardiomyopathy (CMP). This study aims to reveal the true power of this promising approach by synthesizing all the available data on this subject matter. Methods Twenty studies including 1418 patients were identified from systematic search. Weighted mean differences for changes in left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), 6-min walk distance, and NYHA functional class were estimated with a random-effects model. Major adverse cardiovascular event (MACE), rehospitalization, all-cause mortality, and patients’ quality of life were also calculated. Results Compared with the control group, BMC therapy resulted in greater LVEF (3.72%, 95% CI 2.31 to 5.13, P < 0.0001), 6-min walk distance (53.16, 95% CI 25.17 to 81.10, P = 0.0002), NYHA functional class (− 0.48, 95% CI − 0.65 to − 0.31, P < 0.0001), and smaller LVESV (− 16.79, 95% CI − 27.21 to − 6.38, P = 0.002). BMC treatment significantly reduced the mortality rate and improved patients’ quality of life. No significant difference was found between the BMCs and control group in LVEDV, MACE, and rehospitalization rate. However, the outcomes showed a clear trend in favor of the BMC group. Subgroup analysis showed that LVEF improved greater in a subgroup of intracoronary infusion, BMSC, or higher cell dose. Conclusion The results of the current meta-analysis suggest that BMC treatment for CMP is safe and feasible. This therapy was associated with persistent improvements in LV function, LV remodeling, functional class, patients’ survival, and quality of life. Intracoronary infusion of high-dose (> 108) BMSC might be a better therapeutic option for CMP patients. Further evidences are needed to verify our results.http://link.springer.com/article/10.1186/s13287-019-1238-5Bone marrow cellsCardiomyopathyVentricular remodelingVentricular function |
| spellingShingle | Chao Wang Jingzhao Li Boya Zhang Yongjian Li Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis Stem Cell Research & Therapy Bone marrow cells Cardiomyopathy Ventricular remodeling Ventricular function |
| title | Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis |
| title_full | Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis |
| title_fullStr | Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis |
| title_full_unstemmed | Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis |
| title_short | Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis |
| title_sort | safety and efficacy of bone marrow derived cells therapy on cardiomyopathy a meta analysis |
| topic | Bone marrow cells Cardiomyopathy Ventricular remodeling Ventricular function |
| url | http://link.springer.com/article/10.1186/s13287-019-1238-5 |
| work_keys_str_mv | AT chaowang safetyandefficacyofbonemarrowderivedcellstherapyoncardiomyopathyametaanalysis AT jingzhaoli safetyandefficacyofbonemarrowderivedcellstherapyoncardiomyopathyametaanalysis AT boyazhang safetyandefficacyofbonemarrowderivedcellstherapyoncardiomyopathyametaanalysis AT yongjianli safetyandefficacyofbonemarrowderivedcellstherapyoncardiomyopathyametaanalysis |